The paused liver transplant trial provided crucial learnings that informed Quell's pivot to autoimmune diseases. They discovered that high baseline inflammation improves cell engraftment and that durable targets lead to long-term cell activity. These insights gave them confidence to pursue autoimmune indications where these conditions are prevalent.

While in vivo CAR-T therapies eliminate complex ex vivo manufacturing, they introduce a new critical variable: the patient's own immune system. The therapy's efficacy relies on modifying T-cells within the body, but each patient's immune status is different, especially after prior treatments. This makes optimizing and standardizing the dose a significant challenge compared to engineered cell therapies.

The therapy combines low-dose IL-2 to expand T-reg numbers and function, with a CTLA-4 inhibitor to reduce surrounding inflammation. This dual approach addresses a key failure mode of prior T-reg therapies, where newly functional cells would quickly become dysfunctional again in the inflammatory disease environment.

Coya's treatment is a combination therapy that addresses two problems simultaneously. One component increases the number of functional regulatory T-cells (Tregs) to control the immune system. The second component suppresses the underlying inflammation that would otherwise cause these newly boosted cells to become dysfunctional again, ensuring a more durable effect.

A common theme across the four FDA-approved agents for steroid-refractory chronic GVHD (ibrutinib, belumosudil, ruxolitinib, axatilimab) is a high overall response rate driven primarily by partial remissions. The low rate of complete responses (CRs) highlights a significant unmet need and an opportunity for combination therapies or novel mechanisms.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

A core safety feature of Quell's platform is inserting an extra copy of the FOXP3 gene into its Treg cells. This 'phenotype locks' the cells, anchoring them in a suppressive state. This prevents them from flipping into pro-inflammatory 'attacking' cells, which is critical when they are engineered with a CAR to target specific tissues.

Beyond its lead product Orca T for matched donors, the company is building a broader platform. Its Orca Q program addresses mismatched donors, expanding the patient pool. Furthermore, collaborations to combine Orca T with allogeneic CAR-T therapies position the technology as a foundational solution for overcoming key hurdles in the wider cell therapy field.

Quell differentiates its CAR-Treg therapy by aiming to restore immune balance. Unlike B-cell depletion therapies (CAR-T), their approach uses CD19 on B-cells as an activation signal. This creates a local suppressive environment that 'chills' multiple pathogenic cell types (T-cells, B-cells, macrophages) instead of killing just one.